![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GLAXOSMITHKLINE AND CHEMOCENTRYX, INC. ENTER INTO $1.5 BILLION DRUG DISCOVERY AND DEVELOPMENT ALLIANCE IN INFLAMMATORY DISORDERS
GLAXOSMITHKLINE AND CHEMOCENTRYX, INC. ENTER INTO $1.5 BILLION DRUG DISCOVERY AND DEVELOPMENT ALLIANCE IN INFLAMMATORY DISORDERS
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. announced a worldwide multi-target strategic alliance to discover, develop and market novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders, including Traficet-EN in late stage development for the treatment of inflammatory bowel disease (IBD).
This collaboration provides GSK access to selected targets from one of the broadest
pipelines of chemokine-based therapeutics in the biopharmaceutical industry leveraging
ChemoCentryx's expertise and pioneering insight into the chemokine system.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct